EFFECTS OF ANTIHYPERTENSIVE THERAPY ON COGNITIVE DECLINE AND BIOCHEMICAL MARKERS IN HYPERTENSIVE PATIENTS WITH INCREASED RISK FOR ALZHEIMER’S DISEASE

Hypertension is a modifiable risk factor for cognitive decline and Alzheimer's disease (AD). This randomized controlled trial aimed to evaluate the effects of antihypertensive therapy on cognitive function and biochemical markers in hypertensive patients at increased risk for AD. A total of 200 participants aged 60–80 years with diagnosed hypertension and mild cognitive impairment were randomized into two groups: one receiving standard antihypertensive treatment and the other receiving intensive antihypertensive therapy targeting lower blood pressure goals. Over 24 months, cognitive assessments and biochemical analyses, including amyloid-beta and tau protein levels, were conducted. The intensive therapy group showed a statistically significant improvement in cognitive scores (p<0.01) and a reduction in AD-related biomarkers (p<0.05) compared to the standard treatment group. These findings suggest that intensive blood pressure management may slow cognitive decline and modulate biochemical markers associated with AD in hypertensive patients. Further long-term studies are warranted to confirm these results.